T-cell receptor complexed with pp65 peptide:major histocompatibility complex class II

The T-cell receptor complexed with pp65:MHC class II refers to the molecular interaction between a specific T-cell receptor (TCR) on a CD4+ T cell and the major histocompatibility complex (MHC) class II molecule on an antigen-presenting cell that is displaying a peptide derived from the pp65 protein of human cytomegalovirus (HCMV)[1][5][7]. The TCR is a heterodimeric, highly variable receptor (usually comprising α and β chains) of the immunoglobulin superfamily, responsible for recognizing antigenic peptides presented in the context of MHC molecules; in this case, the viral pp65 peptide presented by an MHC class II molecule to CD4+ T cells[1][5][7]. Upon engagement, this complex mediates T-cell activation, proliferation, and effector function, playing a key role in adaptive immunity to viral infections such as CMV and forming the molecular basis for potential immunotherapeutic manipulation, including adoptive T-cell transfer and vaccine design.

Other names

TCR–pp65:MHC-II complexT-cell receptor–pp65–MHC class II complexpp65-specific TCR

Antigen-specific immune activation: Recognition of CMV pp65 peptide presented by MHC class II engages the TCR, leading to T-cell activation, proliferation, and effector functions including cytokine release and targeted cytotoxicity[1][5][7]. - Immunotherapeutic targeting: Engineering T cells to express TCRs specific for pp65:MHC complexes enables targeted cellular immunotherapy for CMV and potentially other settings.